Skip to main content
. 2020 Oct 9;12(10):2897. doi: 10.3390/cancers12102897

Figure 2.

Figure 2

Post-treatment follow-up 18F-FDG PET/CT of the same patient as in Figure 1 after one year. Following anti-programmed death-ligand 1 (PD-L1) immunotherapy (avelumab), both whole-body MIP (A) and transaxial, fused 18F-FDG PET/CT images (B,C) demonstrated complete metabolic remission (CMR) of the previously observed metastases as response to treatment.